CN111182895B - 用于治疗和/或预防微生物感染的葡萄糖酸衍生物 - Google Patents

用于治疗和/或预防微生物感染的葡萄糖酸衍生物 Download PDF

Info

Publication number
CN111182895B
CN111182895B CN201880065162.XA CN201880065162A CN111182895B CN 111182895 B CN111182895 B CN 111182895B CN 201880065162 A CN201880065162 A CN 201880065162A CN 111182895 B CN111182895 B CN 111182895B
Authority
CN
China
Prior art keywords
vaginal
use according
pharmaceutical composition
compound
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880065162.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN111182895A (zh
Inventor
U·埃勒维克
O·斯特内尔
H·斯特雷文斯
S·曼纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gedea Biotech AB
Original Assignee
Gedea Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gedea Biotech AB filed Critical Gedea Biotech AB
Publication of CN111182895A publication Critical patent/CN111182895A/zh
Application granted granted Critical
Publication of CN111182895B publication Critical patent/CN111182895B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126—Acids containing more than four carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880065162.XA 2017-10-06 2018-10-05 用于治疗和/或预防微生物感染的葡萄糖酸衍生物 Active CN111182895B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17195192 2017-10-06
EP17195192.4 2017-10-06
PCT/EP2018/077129 WO2019068862A1 (en) 2017-10-06 2018-10-05 GLUCONIC ACID DERIVATIVES FOR USE IN THE TREATMENT AND / OR PREVENTION OF MICROBIAL INFECTIONS

Publications (2)

Publication Number Publication Date
CN111182895A CN111182895A (zh) 2020-05-19
CN111182895B true CN111182895B (zh) 2024-05-14

Family

ID=60185986

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880065162.XA Active CN111182895B (zh) 2017-10-06 2018-10-05 用于治疗和/或预防微生物感染的葡萄糖酸衍生物

Country Status (21)

Country Link
US (3) US11612584B2 (enExample)
EP (1) EP3691625B1 (enExample)
JP (1) JP7424636B2 (enExample)
KR (1) KR102650182B1 (enExample)
CN (1) CN111182895B (enExample)
AU (1) AU2018346361B2 (enExample)
BR (1) BR112020006931A2 (enExample)
CA (1) CA3078451A1 (enExample)
CL (1) CL2020000859A1 (enExample)
EA (1) EA202090750A1 (enExample)
ES (1) ES3017694T3 (enExample)
HU (1) HUE070746T2 (enExample)
IL (1) IL273297B2 (enExample)
MX (1) MX2020003660A (enExample)
MY (1) MY205944A (enExample)
PH (1) PH12020550222A1 (enExample)
PL (1) PL3691625T3 (enExample)
SG (1) SG11202002494WA (enExample)
UA (1) UA126590C2 (enExample)
WO (1) WO2019068862A1 (enExample)
ZA (1) ZA202001605B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3017694T3 (en) 2017-10-06 2025-05-13 Gedea Biotech Ab Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections
MY208388A (en) 2019-04-05 2025-05-06 Gedea Biotech Ab Vaginal tablet formulation
CN114751878B (zh) * 2022-03-29 2023-06-16 青岛农业大学 一种BcTol1基因靶向剂及其应用
WO2024261110A1 (en) * 2023-06-22 2024-12-26 Gedea Biotech Ab Compositions for promoting growth of lactobacillus crispatus

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1522145A (zh) * 2001-05-01 2004-08-18 ����ڶ�-PPC�ɷ����޹�˾ 用于治疗外阴阴道炎和阴道病的含有抗真菌剂组合物
CN1946291A (zh) * 2004-04-26 2007-04-11 宝洁公司 治疗微生物引起的植物疾病的方法
CN101305993A (zh) * 2007-05-16 2008-11-19 住友化学株式会社 用于抑制家禽球虫感染的组合物以及用其抑制球虫感染的方法
CN109069413A (zh) * 2016-04-06 2018-12-21 盖迪亚生物技术公司 用于治疗阴道真菌感染的葡萄糖酸δ-内酯

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1278868B1 (it) 1995-10-27 1997-11-28 Sanitaria Scaligera Spa Metodo per l'ottenimento di un materiale riassorbibile atto ad essere utilizzato come elemento di rivestimento per la prevenzione di
AUPP839499A0 (en) 1999-01-29 1999-02-25 Australian National University, The A method for controlling plant pathogens, and agents useful for same
JP3745612B2 (ja) 2000-10-31 2006-02-15 西川ゴム工業株式会社 ポリヒドロキシカルボン酸の製造方法
US20060172007A1 (en) * 2001-05-01 2006-08-03 Nawaz Ahmad Compositions and methods for reducing vaginal pH
US20060105008A1 (en) 2002-03-28 2006-05-18 Nawaz Ahmad Compositions and methods for reducing vaginal pH
CA2487270C (en) 2002-06-21 2010-10-26 The Procter & Gamble Company Antimicrobial compositions, products and methods employing same
US7569530B1 (en) 2003-06-20 2009-08-04 The Procter & Gamble Company Antimicrobial compositions, products and methods employing same
US7547454B2 (en) * 2002-11-07 2009-06-16 Shyam K Gupta Hydroxy acid complexes for antiaging and skin renovation
US20040126369A1 (en) * 2002-12-30 2004-07-01 Richard Payne Delivery of peroxide-generating enzymes to the vaginal tract
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US20050271711A1 (en) 2004-04-26 2005-12-08 The Procter & Gamble Company Therapeutic antimicrobial compositions and methods
AU2006209263A1 (en) 2005-09-12 2007-03-29 Mcneil-Ppc, Inc. Anhydrous composition containing an acid-acid buffer system
US20070059278A1 (en) 2005-09-12 2007-03-15 Nawaz Ahmad Anhydrous composition containing an acid-acid buffer system
US20080058421A1 (en) * 2006-09-05 2008-03-06 John Alex Lopes Compositions for cleaning and disinfecting nasal tract and sinus cavity
WO2008108834A2 (en) * 2006-11-09 2008-09-12 Northwestern University Inhibitors of the mevalonate pathway of streptococcus pneumoniae
US20100285095A1 (en) * 2009-05-05 2010-11-11 Kimberly Ann Nemeth Hygiene Article Having Calcium Sugar Acid Salt
CN102070774B (zh) 2010-11-25 2012-08-22 华南师范大学 单糖或其糖醇与乳酸的共聚物的制备方法
MX2013012745A (es) 2011-05-02 2014-12-05 Aptalis Pharmatech Inc Composiciones en forma de comprmido de disolución rápida para administración vaginal.
MY172685A (en) 2013-11-08 2019-12-10 Suzhou Osel Bio Pharm Co Ltd A lactobacillus crispatus and application thereof
DK178786B1 (en) * 2015-03-11 2017-02-06 Dantrace-Danfeed Ivs Use of zinc and copper gluconate in the treatment of methicillin-resistant staphylococcus aureus
JP7219712B2 (ja) 2016-10-13 2023-02-08 キャタレント・ユーケー・スウィンドン・ザイディス・リミテッド 膣送達のための凍結乾燥医薬組成物
KR101841976B1 (ko) 2017-06-07 2018-05-14 조영진 식물 추출물을 포함하는 항진균 및 항균 조성물
ES3017694T3 (en) 2017-10-06 2025-05-13 Gedea Biotech Ab Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections
MY208388A (en) 2019-04-05 2025-05-06 Gedea Biotech Ab Vaginal tablet formulation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1522145A (zh) * 2001-05-01 2004-08-18 ����ڶ�-PPC�ɷ����޹�˾ 用于治疗外阴阴道炎和阴道病的含有抗真菌剂组合物
CN1946291A (zh) * 2004-04-26 2007-04-11 宝洁公司 治疗微生物引起的植物疾病的方法
CN101305993A (zh) * 2007-05-16 2008-11-19 住友化学株式会社 用于抑制家禽球虫感染的组合物以及用其抑制球虫感染的方法
CN109069413A (zh) * 2016-04-06 2018-12-21 盖迪亚生物技术公司 用于治疗阴道真菌感染的葡萄糖酸δ-内酯

Also Published As

Publication number Publication date
KR102650182B1 (ko) 2024-03-21
US20200253925A1 (en) 2020-08-13
SG11202002494WA (en) 2020-04-29
PH12020550222A1 (en) 2021-02-15
MX2020003660A (es) 2020-08-03
BR112020006931A2 (pt) 2020-10-06
UA126590C2 (uk) 2022-11-02
CA3078451A1 (en) 2019-04-11
PL3691625T3 (pl) 2025-05-12
JP2020536862A (ja) 2020-12-17
ES3017694T3 (en) 2025-05-13
EP3691625A1 (en) 2020-08-12
CN111182895A (zh) 2020-05-19
IL273297B1 (en) 2024-02-01
CL2020000859A1 (es) 2020-10-02
AU2018346361B2 (en) 2024-07-25
US11612584B2 (en) 2023-03-28
ZA202001605B (en) 2023-12-20
AU2018346361A1 (en) 2020-05-14
JP7424636B2 (ja) 2024-01-30
US12226396B2 (en) 2025-02-18
US20230181523A1 (en) 2023-06-15
EP3691625B1 (en) 2025-02-19
HUE070746T2 (hu) 2025-07-28
MY205944A (en) 2024-11-21
US20250144070A1 (en) 2025-05-08
EP3691625C0 (en) 2025-02-19
WO2019068862A1 (en) 2019-04-11
EA202090750A1 (ru) 2020-11-11
IL273297B2 (en) 2024-06-01
KR20200060413A (ko) 2020-05-29
IL273297A (en) 2020-04-30

Similar Documents

Publication Publication Date Title
US12226396B2 (en) Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections
AU2011343012B2 (en) A composition comprising an antibiotic and a dispersant or an anti -adhesive agent
JP6780123B2 (ja) 静菌剤配合の膣用組成物の調製への用途及び膣用組成物
ES2532884T3 (es) Composición vaginal a base de alquilpoliglucósidos
CN105232526A (zh) 含儿茶素的药物在制备抑菌药物中的用途
CN102048729B (zh) 一种治疗阴道炎的制剂
CN109069413B (zh) 用于治疗阴道真菌感染的葡萄糖酸δ-内酯
CN116077622B (zh) 用于防治奶牛乳房炎的奶头药浴涂膜剂及其制备方法与应用
TW202328169A (zh) 治療細菌性陰道炎的方法和組合物
KR101296009B1 (ko) 질 및 외음 감염의 예방 및/또는 치료 방법
US7704976B2 (en) Use of N-acetyl-D-glucosamine for preparing medicines for urogenital tract infection's treatment and prevention
CN111973571B (zh) 基于小檗碱衍生物及鼠李糖脂的抗菌纳米粒
WO2024262189A1 (ja) 細菌の増殖抑制剤、それを含む化粧品、医薬部外品、及び医薬組成物、並びに細菌の増殖抑制方法
RU2595852C1 (ru) Антимикробные суппозитории
JP2025151411A (ja) 細菌性膣症の抑制剤、細菌性膣症関連細菌のオートインデューサー－２阻害剤、細菌性膣症関連細菌のバイオフィルム形成の抑制剤、細菌性膣症関連細菌に対する抗菌薬抗菌力の増強剤、及び当該抗菌力の増強方法
RU2793626C2 (ru) Алкилрезорцины в качестве цитопротективного агента
JP2019521134A (ja) 性感染症用組成物
CN119868321A (zh) 根皮素在制备肺炎克雷伯菌荚膜抑制剂中的医用用途
HK1183454B (en) Tamarind seed polysaccharide for use in the treatment of microbial infections
HK1183454A1 (zh) 用於治疗微生物感染的罗望子种子多糖

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant